|
Suramin in Treating Patients With Recurrent Primary Brain Tumors Clinical Trials Resources presented on Clinical Trials Search isn't meant to be a substitute for qualified health advice, visits or professional assistance with a real medical. We aren't doctors. Always consult your mD about Suramin in Treating Patients With Recurrent Primary Brain Tumors conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Suramin in Treating Patients With Recurrent Primary Brain Tumors Clinical research trials and Suramin in Treating Patients With Recurrent Primary Brain Tumors health trials occur in a lot of of places throughout the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectivity of new does drugs. The role of the studies / projects is to resolve certain human healthcare questions. Clinical trials are a popular way for doctors, government agencies, and private sector corporations to detect remedies for all varieties of circumstances, such as Suramin in Treating Patients With Recurrent Primary Brain Tumors. Suramin in Treating Patients With Recurrent Primary Brain Tumors Clinical Trials and other clinical trials allow volunteers to obtain health treatment choices before they are available to the general public. Most times the human subjects recieve professional assistance for free of charge, and every now and again they are paid for their time. Sometimes there is a cost for a Suramin in Treating Patients With Recurrent Primary Brain Tumors clinical trial. Human subjects frequently get the finest healthcare available for their Suramin in Treating Patients With Recurrent Primary Brain Tumors condition. Risks are a reality, however, and may include extra or frequent physician visits, medical dangers (possibly life-threatening), and/or the treatment being uneffective. Trials are federally governed with strict guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "S" Clinical Trials Conditions > Suramin in Treating Patients With Recurrent Primary Brain Tumors  Suramin in Treating Patients With Recurrent Primary Brain Tumors
Suramin in Treating Patients With Recurrent Primary Brain Tumors
For Condition: adult anaplastic oligodendroglioma,adult glioblastoma multiforme,adult anaplastic astrocytoma,Mixed Gliomas,recurrent adult brain tumor
Status: Completed
Sponsor(s): National Cancer Institute (NCI) , Emory University
Synopsis: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of suramin in treating patients with recurrent primary brain tumors following radiation therapy.
Details: OBJECTIVES: I. Estimate the efficacy of suramin in patients with recurrent primary brain tumors as measured by radiographic response, time to progression, and survival. II. Assess the toxic effects of suramin in this patient population. PROTOCOL OUTLINE: Single-Agent Chemotherapy. Suramin, SUR, NSC-34936. PROJECTED ACCRUAL: If at least 1 of the first 14 patients experiences at least a partial response, a total of 25 patients will be entered over approximately 30 months.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 15 Years/
Genders:
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- - Recurrent brain tumor based on one of the following: Tissue diagnosis if there was a prior diagnosis of astrocytoma or oligodendroglioma or if there is a question of radiation necrosis from prior interstitial brachytherapy - Metabolic activity in excess of normal cortex measured by 18-fluorodeoxyglucose uptake on PET - One of the following histologic types required: Glioblastoma multiforme; Anaplastic astrocytoma; Anaplastic oligodendroglioma; Anaplastic mixed glioma - Tumor progression required, i.e.: 28% increase in contrast-enhancing area or 50% increase in contrast-enhancing volume over at least 4 weeks - Measurable disease required - No history, surgical findings, or radiographic signs of intratumoral hemorrhage --Prior/Concurrent Therapy-- - Biologic therapy: Not specified - Chemotherapy: No prior chemotherapy for glioblastoma multiforme; No more than 1 prior chemotherapy regimen for anaplastic astrocytoma, malignant oligodendroglioma, or malignant mixed glioma; At least 4 weeks since chemotherapy (6 weeks since nitrosoureas or mitomycin) - Endocrine therapy: Not specified - Radiotherapy: Completion of 1 course of conventional external radiotherapy required; At least 4 weeks since radiotherapy - Surgery: Decompressive surgery for clinically suspected increased intracranial pressure performed prior to entry --Patient Characteristics-- - Age: Over 15 - Performance status: Karnofsky 50%-100% - Life expectancy: At least 12 weeks - Hematopoietic: WBC at least 3,000; Platelets at least 75,000 - Hepatic: Bilirubin less than 1.5 mg/dL; AST/ALT less than 3 times normal; No history of bleeding disorder; No hepatic disease resulting in hospitalization - Renal: Creatinine less than 1.5 mg/dL; No renal disease resulting in hospitalization - Cardiovascular: No ongoing anticoagulation for deep vein thrombosis (DVT); No residual symptoms from DVT after discontinuation of anticoagulation; No cardiac disease resulting in hospitalization - Pulmonary: No pulmonary disease resulting in hospitalization - Other: No peripheral neuropathy of any etiology; HIV negative; No pregnant or nursing women; Adequate contraception required during and for 12 months following protocol therapy
Total Enrollment:
Location and Contact Information:
Overall Study Official:
JeffreyOlson, Study Chair, Emory University
Department of Neurosurgery - Emory
Atlanta, Georgia, 30322
United States
Additional Information:
Study ID Numbers: CDR0000064118; EUC-DON-9420,NCI-T94-0033O
Study Start Date: July 1995
Record last reviewed: May 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00002639
Other Mixed Gliomas Studies:
1. ZD 1839 in Treating Patients With Glioblastoma Multiforme in First Relapse
2. Fenretinide in Treating Patients With Recurrent Malignant Glioma
3. Carmustine Plus O6-benzylguanine in Treating Patients With Recurrent or Progressive Glioma
4. Alanosine in Treating Patients With Progressive or Recurrent Malignant Gliomas
5. Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Mixed Gliomas
Related Studies:
Other Mixed Gliomas Clinical Trials
Other Georgia Clinical Trials
Other Atlanta Clinical Trials
Suramin in Treating Patients With Recurrent Primary Brain Tumors
|
|
|
|
|
|
|
|
